ADAPTOS - Changing the way bone voids are treated

ended

There are 4 million operations performed annually that require a bone graft. This makes bone the second most common tissue transplant in the world, trailing only blood transfusions. There are three options where to source the bone today. Directly from the patient (autograft), from a bone bank (allograft) or using a substitute. The dominant method today is autografting. This is because human’s own bone is easy to use and offers plentiful regeneration properties. However, autografting is painful and risky, causing complications in 50% of harvests. This has caused orthopaedic surgeons to regard autografting as a trade-off between sourcing a suitable bone at the cost of a minor disability for the patient. This is where Adaptos comes in. Adaptos is the only bone graft substitute that mimics bone by being resilient and bioactive. Adaptos gives surgeons the freedom to operate, as they were using autografts, without the drawbacks. Today, Adaptos is already in use across 9 animal clinics. By collaborating with numerous surgeons, we have validated our technology as the best bone graft substitute on the market. We will initially enter the synthetic bone graft substitute market valued at €2.1 billion. We aim to penetrate the less complex markets first (animals, craniomaxillofacial & orthopaedic applications). Through these applications, we will build reference cases to meet the high burden-of-proof required to enter the most complex applications (e.g. Spinal fusion). Our cross-disciplinary founding team will use the SME-project to scale up Adaptos’ production line, build reference cases across 3 hospitals via a multi-country clinical trial and improve our onboarding of orthopaedic surgeons in the process. Thanks to the SME-project, we estimate that we will reach €17 million in revenue by 2023 while employing 35 high-quality employees.